miltefosine has been researched along with Recrudescence in 45 studies
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.
| Excerpt | Relevance | Reference |
|---|---|---|
| " One hundred and fifty patients aged ≥18 years with serologically confirmed HIV and parasitologically confirmed VL were randomly allocated to 1 of 2 treatment arms, either a total 40 mg/kg intravenous liposomal amphotericin B (AmBisome; Gilead Pharmaceuticals) administered in 8 equal doses over 24 days or a total 30 mg/kg intravenous AmBisome administered in 6 equal doses given concomitantly with a total 1." | 5.51 | AmBisome Monotherapy and Combination AmBisome-Miltefosine Therapy for the Treatment of Visceral Leishmaniasis in Patients Coinfected With Human Immunodeficiency Virus in India: A Randomized Open-Label, Parallel-Arm, Phase 3 Trial. ( Alexander, N; Alves, F; Burza, S; Das, P; Das, VNR; de Lima Pereira, A; Gill, N; Goyal, V; Harshana, A; Kazmi, S; Kumar, D; Kumar, V; Lal, CS; Lasry, E; Mahajan, R; Pandey, K; Rewari, B; Rijal, S; Verma, N, 2022) |
| "Visceral leishmaniasis is an opportunistic infection that affects human immunodeficiency virus-infected persons in leishmaniasis-endemic areas." | 5.36 | Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient. ( Barragán, P; López-Velez, R; Olmo, M; Podzamczer, D, 2010) |
| "Embedded in a clinical trial in Northwest Ethiopia, RNA-Seq was performed on whole blood samples of 28 VL-HIV patients before and after completion of a 29-day treatment regimen of AmBisome or AmBisome/miltefosine." | 5.34 | Host transcriptomic signature as alternative test-of-cure in visceral leishmaniasis patients co-infected with HIV. ( Adriaensen, W; Alves, F; Blesson, S; Cnops, L; Cordero, CF; Cuypers, B; Diro, E; Kaye, PM; Mengasha, B; van Griensven, J, 2020) |
| " Combination regimens including AmBisome, paromomycin and miltefosine have proved to be safe and effective in the treatment of VL in India." | 2.84 | Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh. ( Alvar, J; Alves, F; Balasegaram, M; Boer, MD; Ellis, S; Faiz, A; Goyal, V; Haque, R; Jamil, K; Rahman, R; Rijal, S; Samad, R; Sharma, B; Strub-Wourgaft, N, 2017) |
| "Miltefosine drug exposure was found to be decreased in Eastern African patients with visceral leishmaniasis, due to a (transient) initial lower bioavailability." | 2.84 | Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study. ( Alves, F; Balasegaram, M; Beijnen, JH; Dorlo, TPC; Ellis, SJ; Hailu, A; Karlsson, MO; Khalil, EAG; Kip, AE; Kirigi, G; Musa, AM; Njenga, S; Olobo, J; Wasunna, M; Younis, BM, 2017) |
| " The adverse effects were primarily gastrointestinal for miltefosine and pain at the lesion site after treatment for thermotherapy." | 2.78 | Thermotherapy effective and safer than miltefosine in the treatment of cutaneous leishmaniasis in Colombia. ( Cruz, C; Godoy, G; López, L; Robledo, SM; Vélez, ID, 2013) |
| "Combination treatments for visceral leishmaniasis are efficacious and safe, and decrease the duration of therapy, thereby encouraging adherence and reducing emergence of drug-resistant parasites." | 2.76 | Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. ( Alam, S; Arora, R; Balasegaram, M; Chakravarty, J; Das, P; Ellis, S; Kumari, P; Lal, CS; Modabber, F; Nawin, K; Olliaro, P; Pandey, K; Rai, M; Sharma, B; Sinha, PK; Strub-Wourgaft, N; Sundar, S; Vaillant, M; Verma, DK; Verma, N, 2011) |
| "Miltefosine is an oral agent that has been shown in small numbers of patients to have a favorable therapeutic index for Indian visceral leishmaniasis." | 2.70 | Oral miltefosine for Indian visceral leishmaniasis. ( Berman, J; Bryceson, A; Engel, J; Fischer, C; Jha, TK; Junge, K; Sindermann, H; Sundar, S; Thakur, CP, 2002) |
| "Miltefosine is a phosphocholine analogue that affects cell-signaling pathways and membrane synthesis." | 2.69 | Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. ( Bachmann, P; Berman, J; Fischer, C; Jha, TK; Karbwang, J; Sundar, S; Thakur, CP; Voss, A, 1999) |
| "Frequent relapses are observed in co-infected HIV who can benefit of a second cycle." | 2.55 | Visceral leishmaniosis in immunocompromised host: an update and literature review. ( Esposito, S; Pagliano, P, 2017) |
| " This study aimed to investigate the feasibility of using focused pharmacovigilance for VL (VLPV) in Bangladesh's National Kala-azar Elimination Programme for the early detection and prevention of expected and unexpected adverse drug reactions (ADRs)." | 1.48 | Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme. ( Ahuja, V; Ghosh, P; Haque, R; Hossain, AFMA; Hossain, MA; Hossain, MS; Kumar, A; Mahshin, M; Maruf, S; Mondal, D; Shamsuzzaman, AKM; Sharma, A; Sharma, V, 2018) |
| "Miltefosine (MIL) is an oral antileishmanial drug used for treatment of visceral leishmaniasis (VL) in the Indian subcontinent." | 1.46 | Increased miltefosine tolerance in clinical isolates of Leishmania donovani is associated with reduced drug accumulation, increased infectivity and resistance to oxidative stress. ( Bhandari, V; Deep, DK; Dujardin, JC; Ramesh, V; Salotra, P; Sharma, V; Singh, R; Sundar, S; Verma, A; Wajid, S, 2017) |
| "Treatments by miltefosine, amphotericin B, N-methyl-glucamine antimoniate were subsequently initiated." | 1.46 | Recurrence of visceral and muco-cutaneous leishmaniasis in a patient under immunosuppressive therapy. ( Arrese Estrada, J; Cnops, L; Darcis, G; de Leval, L; Giot, JB; Hayette, MP; Leonard, P; Moutschen, M; Tassin, F; Van der Auwera, G, 2017) |
| "In this study 86 confirmed cases of PKDL were treated with two different dosage regimens of miltefosine (Regimen I- 50mg twice daily for 90 days and Regimen II- 50 mg thrice for 60 days) and the clinical outcome assessed monthly." | 1.42 | Decline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India. ( Avishek, K; Deep, DK; Ramesh, V; Salotra, P; Singh, R; Verma, A; Verma, S, 2015) |
| "To identify epidemiological and clinical risk factors for relapse of VL in patients recently treated with standard dosing of miltefosine in India and Nepal." | 1.40 | Failure of miltefosine treatment for visceral leishmaniasis in children and men in South-East Asia. ( Boelaert, M; Dorlo, TP; Dujardin, JC; Hasker, E; Ostyn, B; Rijal, S; Sundar, S, 2014) |
| "Parasite fingerprints of pretreatment and relapse bone marrow isolates within 8 patients were similar, suggesting that clinical relapses were not due to reinfection with a new strain." | 1.39 | Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. ( Beijnen, JH; Bhattarai, NR; Boelaert, M; Das, ML; Decuypere, S; Dhakal, SS; Dorlo, TP; Dujardin, JC; Karki, P; Ostyn, B; Rai, K; Rijal, S; Singh, R; Uranw, S; Vanaerschot, M, 2013) |
| "Miltefosine is an option for treating Old World leishmaniasis (Leishmania infantum) and immunodeficiency should be considered in patients with recurrent leishmaniasis." | 1.39 | Treatment of mucosal leishmaniasis (L. infantum) with miltefosine in a patient with Good syndrome. ( Arnold, A; Blum, J; Holbro, A; Neumayr, A; Stoeckle, M; Weisser, M, 2013) |
| "Visceral leishmaniasis is an opportunistic infection that affects human immunodeficiency virus-infected persons in leishmaniasis-endemic areas." | 1.36 | Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient. ( Barragán, P; López-Velez, R; Olmo, M; Podzamczer, D, 2010) |
| "Miltefosine is a less toxic option to replace the antimony compounds." | 1.34 | [Cutaneous leishmaniasis]. ( Sunderkötter, C; von Stebut, E, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.22) | 18.2507 |
| 2000's | 10 (22.22) | 29.6817 |
| 2010's | 27 (60.00) | 24.3611 |
| 2020's | 7 (15.56) | 2.80 |
| Authors | Studies |
|---|---|
| Burza, S | 5 |
| Mahajan, R | 3 |
| Kazmi, S | 1 |
| Alexander, N | 1 |
| Kumar, D | 3 |
| Kumar, V | 1 |
| Lasry, E | 1 |
| Harshana, A | 1 |
| de Lima Pereira, A | 1 |
| Das, P | 5 |
| Verma, N | 3 |
| Das, VNR | 2 |
| Lal, CS | 3 |
| Rewari, B | 1 |
| Goyal, V | 3 |
| Rijal, S | 7 |
| Alves, F | 5 |
| Gill, N | 1 |
| Pandey, K | 6 |
| de Jong, MK | 1 |
| Rappoldt, A | 1 |
| Broere, F | 1 |
| Piek, CJ | 1 |
| Mano, C | 1 |
| Kongkaew, A | 1 |
| Tippawangkosol, P | 1 |
| Junkum, A | 1 |
| Siriyasatien, P | 1 |
| Jariyapan, N | 1 |
| Singh, SN | 1 |
| Singh, RS | 1 |
| Strub-Wourgaft, N | 3 |
| Bern, C | 1 |
| Hightower, A | 1 |
| Sunyoto, T | 2 |
| Lima, N | 1 |
| Alvar, J | 2 |
| Ramesh, V | 3 |
| Dixit, KK | 1 |
| Sharma, N | 1 |
| Singh, R | 4 |
| Salotra, P | 3 |
| Camilleri, M | 1 |
| Richards, H | 1 |
| Pomplun, S | 1 |
| Wilson, A | 1 |
| Checkley, A | 1 |
| Rabin, N | 1 |
| Adriaensen, W | 1 |
| Cuypers, B | 2 |
| Cordero, CF | 1 |
| Mengasha, B | 1 |
| Blesson, S | 1 |
| Cnops, L | 2 |
| Kaye, PM | 1 |
| Diro, E | 1 |
| van Griensven, J | 1 |
| Jaiteh, MB | 1 |
| İnkaya, AÇ | 1 |
| Üner, A | 1 |
| Elçin, G | 1 |
| Ergüven, S | 1 |
| Kurtulan, O | 1 |
| Harxhi, A | 1 |
| Akova, M | 1 |
| Pagliano, P | 1 |
| Esposito, S | 1 |
| Rahman, R | 1 |
| Haque, R | 2 |
| Jamil, K | 1 |
| Faiz, A | 1 |
| Samad, R | 1 |
| Ellis, S | 2 |
| Balasegaram, M | 3 |
| Boer, MD | 1 |
| Sharma, B | 2 |
| Deep, DK | 2 |
| Bhandari, V | 1 |
| Verma, A | 2 |
| Sharma, V | 2 |
| Wajid, S | 1 |
| Sundar, S | 7 |
| Dujardin, JC | 6 |
| Darcis, G | 1 |
| Van der Auwera, G | 1 |
| Giot, JB | 1 |
| Hayette, MP | 1 |
| Tassin, F | 1 |
| Arrese Estrada, J | 1 |
| Moutschen, M | 1 |
| de Leval, L | 1 |
| Leonard, P | 1 |
| Dorlo, TPC | 1 |
| Kip, AE | 1 |
| Younis, BM | 1 |
| Ellis, SJ | 1 |
| Beijnen, JH | 2 |
| Njenga, S | 1 |
| Kirigi, G | 1 |
| Hailu, A | 1 |
| Olobo, J | 1 |
| Musa, AM | 1 |
| Wasunna, M | 1 |
| Karlsson, MO | 1 |
| Khalil, EAG | 1 |
| Tiwary, P | 1 |
| Hossain, MS | 1 |
| Kumar, A | 1 |
| Hossain, AFMA | 1 |
| Mahshin, M | 1 |
| Sharma, A | 1 |
| Hossain, MA | 1 |
| Shamsuzzaman, AKM | 1 |
| Maruf, S | 1 |
| Ghosh, P | 1 |
| Ahuja, V | 1 |
| Mondal, D | 1 |
| Hendrickx, S | 3 |
| Bulté, D | 1 |
| Van den Kerkhof, M | 1 |
| Cos, P | 2 |
| Delputte, P | 2 |
| Maes, L | 3 |
| Caljon, G | 2 |
| Ostyn, B | 3 |
| Uranw, S | 2 |
| Rai, K | 2 |
| Bhattarai, NR | 3 |
| Dorlo, TP | 2 |
| Vanaerschot, M | 3 |
| Decuypere, S | 1 |
| Dhakal, SS | 1 |
| Das, ML | 1 |
| Karki, P | 1 |
| Boelaert, M | 3 |
| López, L | 1 |
| Cruz, C | 1 |
| Godoy, G | 1 |
| Robledo, SM | 1 |
| Vélez, ID | 1 |
| Stoeckle, M | 1 |
| Holbro, A | 1 |
| Arnold, A | 1 |
| Neumayr, A | 1 |
| Weisser, M | 1 |
| Blum, J | 1 |
| Nabi, E | 1 |
| Mitra, G | 2 |
| Lima, MA | 2 |
| Berg, M | 1 |
| Dumetz, F | 1 |
| Roy, S | 2 |
| Ponte-Sucre, A | 1 |
| Arevalo, J | 1 |
| Patole, S | 1 |
| Varghese, GM | 1 |
| Hasker, E | 1 |
| Isaakidis, P | 1 |
| Sagili, KD | 1 |
| Van Geertruyden, JP | 1 |
| Ghosh, S | 1 |
| Das, NK | 1 |
| Mukherjee, S | 1 |
| Mukhopadhyay, D | 1 |
| Barbhuiya, JN | 1 |
| Hazra, A | 1 |
| Chatterjee, M | 2 |
| Eberhardt, E | 1 |
| Mondelaers, A | 1 |
| Ganguly, S | 1 |
| Saha, P | 1 |
| Ghosh, TK | 1 |
| Guha, SK | 1 |
| Kundu, PK | 1 |
| Bera, DK | 1 |
| Basu, N | 1 |
| Maji, AK | 1 |
| Avishek, K | 1 |
| Verma, S | 1 |
| Guerin, PJ | 1 |
| Croft, SL | 1 |
| Manna, L | 1 |
| Vitale, F | 1 |
| Reale, S | 1 |
| Picillo, E | 1 |
| Neglia, G | 1 |
| Vescio, F | 1 |
| Gravino, AE | 1 |
| Pandey, BD | 1 |
| Kaneko, O | 1 |
| Yanagi, T | 1 |
| Hirayama, K | 1 |
| Barragán, P | 1 |
| López-Velez, R | 1 |
| Olmo, M | 1 |
| Podzamczer, D | 1 |
| Sinha, PK | 2 |
| Rai, M | 1 |
| Verma, DK | 1 |
| Nawin, K | 1 |
| Alam, S | 1 |
| Chakravarty, J | 1 |
| Vaillant, M | 1 |
| Kumari, P | 1 |
| Arora, R | 1 |
| Olliaro, P | 1 |
| Modabber, F | 1 |
| Kumar, N | 1 |
| Ranjan, A | 1 |
| Verma, RB | 1 |
| Cojean, S | 1 |
| Houzé, S | 1 |
| Haouchine, D | 1 |
| Huteau, F | 1 |
| Lariven, S | 1 |
| Hubert, V | 1 |
| Michard, F | 1 |
| Bories, C | 1 |
| Pratlong, F | 2 |
| Le Bras, J | 1 |
| Loiseau, PM | 1 |
| Matheron, S | 1 |
| Jha, TK | 2 |
| Thakur, CP | 2 |
| Engel, J | 1 |
| Sindermann, H | 3 |
| Fischer, C | 2 |
| Junge, K | 1 |
| Bryceson, A | 1 |
| Berman, J | 2 |
| Bommer, W | 1 |
| Eibl, HJ | 1 |
| Engel, KR | 1 |
| Kuhlencord, A | 1 |
| Zappel, H | 1 |
| Rihl, M | 1 |
| Stoll, M | 1 |
| Ulbricht, K | 1 |
| Bange, FC | 1 |
| Schmidt, RE | 1 |
| Calvopina, M | 1 |
| Gomez, EA | 1 |
| Cooper, PJ | 1 |
| Hashiguchi, Y | 1 |
| Iqbal, J | 1 |
| Bukhari, I | 1 |
| Jamshid, M | 1 |
| Bashir, S | 1 |
| Masoom Yasinzai, M | 1 |
| Anwar, M | 1 |
| Zerpa, O | 1 |
| Ulrich, M | 1 |
| Blanco, B | 1 |
| Polegre, M | 1 |
| Avila, A | 1 |
| Matos, N | 1 |
| Mendoza, I | 1 |
| Ravel, C | 1 |
| Convit, J | 1 |
| von Stebut, E | 1 |
| Sunderkötter, C | 1 |
| Wysluch, A | 1 |
| Sommerer, F | 1 |
| Ramadan, H | 1 |
| Loeffelbein, D | 1 |
| Wolff, KD | 1 |
| Hölzle, F | 1 |
| Bachmann, P | 1 |
| Karbwang, J | 1 |
| Voss, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III, Open Label, Randomised, Study of Three Short Course Combination Regimens (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome® Alone for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh[NCT01122771] | Phase 3 | 602 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
| Phase 3 Open-label Study of Efficacy and Safety of Miltefosine or Thermotherapy vs Glucantime for Cutaneous Leishmaniasis in Colombia.[NCT00471705] | Phase 3 | 437 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Randomized, Open-label, Parallel-group, Safety & Efficacy Study to Evaluate Different Combination Treatment Regimens, of Either AmBisome and Paromomycin, AmBisome and Miltefosine, or Paromomycin and Miltefosine Compared With Amphotericin B Deoxycholate (t[NCT00696969] | Phase 3 | 634 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Complete Clinical response: Initial cure plus the absence of recurrences or mucosal lesions for 6 months after the end of treatment.~Note: nitial cure: Complete re-epithelialization of all ulcers and complete disappearance of the induration up to 3 months after the end of treatment." (NCT00471705)
Timeframe: Until 6 months posttreatment
| Intervention | participants (Number) |
|---|---|
| Miltefosine | 85 |
| Glucantime® | 103 |
| Thermotherapy | 86 |
At least 50% increase in lesion size at the end of treatment, absence of clinical response at 6 weeks, or any sign of lesion activity 3 months after the end of treatment (NCT00471705)
Timeframe: Until 3 months posttreatment
| Intervention | participants (Number) |
|---|---|
| Miltefosine | 34 |
| Glucantime® | 14 |
| Thermotherapy | 42 |
Reactivation of the lesion at the original site after cure or mucosal compromise during follow-up. (NCT00471705)
Timeframe: Until 6 months post-treatment
| Intervention | Participants (Number) |
|---|---|
| Miltefosine | 3 |
| Glucantime® | 4 |
| Thermotherapy | 6 |
4 reviews available for miltefosine and Recrudescence
| Article | Year |
|---|---|
Visceral leishmaniosis in immunocompromised host: an update and literature review.
Topics: Amphotericin B; HIV Infections; Humans; Immunocompromised Host; Leishmaniasis, Visceral; Phosphorylc | 2017 |
Treatment failure in leishmaniasis: drug-resistance or another (epi-) phenotype?
Topics: Animals; Antiprotozoal Agents; Drug Resistance; Humans; Insect Vectors; Leishmania; Leishmaniasis; P | 2014 |
Evaluating drug resistance in visceral leishmaniasis: the challenges.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Resistance, Multiple; Humans; Leishmania donovan | 2018 |
[The leishmaniasis - a parasitel infection as differential diagnosis of malignant tumours of oral mucosa. A case report and review of literature].
Topics: Animals; Combined Modality Therapy; Diagnosis, Differential; Hepatitis C, Chronic; Histiocytes; Huma | 2007 |
9 trials available for miltefosine and Recrudescence
| Article | Year |
|---|---|
AmBisome Monotherapy and Combination AmBisome-Miltefosine Therapy for the Treatment of Visceral Leishmaniasis in Patients Coinfected With Human Immunodeficiency Virus in India: A Randomized Open-Label, Parallel-Arm, Phase 3 Trial.
Topics: Adolescent; Adult; Amphotericin B; Antiprotozoal Agents; Coinfection; Drug Therapy, Combination; HIV | 2022 |
Host transcriptomic signature as alternative test-of-cure in visceral leishmaniasis patients co-infected with HIV.
Topics: Adult; Amphotericin B; Antiprotozoal Agents; Coinfection; Endoribonucleases; Female; Gene Expression | 2020 |
Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.
Topics: Adolescent; Adult; Amphotericin B; Antiprotozoal Agents; Bangladesh; Child; Child, Preschool; Drug T | 2017 |
Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study.
Topics: Adolescent; Adult; Africa, Eastern; Antiprotozoal Agents; Biological Availability; Child; Female; Hu | 2017 |
Thermotherapy effective and safer than miltefosine in the treatment of cutaneous leishmaniasis in Colombia.
Topics: Adult; Antiprotozoal Agents; Colombia; Follow-Up Studies; Humans; Hyperthermia, Induced; Leishmanias | 2013 |
Inadequacy of 12-Week Miltefosine Treatment for Indian Post-Kala-Azar Dermal Leishmaniasis.
Topics: Adolescent; Adult; Antiprotozoal Agents; Child; Drug Administration Schedule; Female; Humans; Leishm | 2015 |
Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
Topics: Adolescent; Adult; Amphotericin B; Antiprotozoal Agents; Child; Child, Preschool; Creatinine; Dose-R | 2011 |
Oral miltefosine for Indian visceral leishmaniasis.
Topics: Administration, Oral; Adolescent; Adult; Amphotericin B; Animals; Antiprotozoal Agents; Female; Huma | 2002 |
Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis.
Topics: Administration, Oral; Adolescent; Adult; Antiprotozoal Agents; Aspartate Aminotransferases; Female; | 1999 |
32 other studies available for miltefosine and Recrudescence
| Article | Year |
|---|---|
Survival time and prognostic factors in canine leishmaniosis in a non-endemic country treated with a two-phase protocol including initial allopurinol monotherapy.
Topics: Allopurinol; Animals; Creatinine; Dog Diseases; Dogs; Humans; Leishmania infantum; Leishmaniasis; Le | 2023 |
In vitro susceptibility to miltefosine of amphotericin B-resistant Leishmania (Mundinia) martiniquensis.
Topics: Amphotericin B; Antiprotozoal Agents; Chronic Disease; Humans; Leishmania; Leishmaniasis; Leishmania | 2023 |
Field effectiveness of new visceral leishmaniasis regimens after 1 year following treatment within public health facilities in Bihar, India.
Topics: Adolescent; Amphotericin B; Antiprotozoal Agents; Child; Child, Preschool; Cohort Studies; Drug Ther | 2019 |
Assessing the Efficacy and Safety of Liposomal Amphotericin B and Miltefosine in Combination for Treatment of Post Kala-Azar Dermal Leishmaniasis.
Topics: Adolescent; Adult; Amphotericin B; Antiprotozoal Agents; Child; DNA, Protozoan; Drug Therapy, Combin | 2020 |
Leishmaniasis as an unusual cause of pancytopenia in a patient receiving immunomodulatory therapy for myeloma.
Topics: Aged; Antiprotozoal Agents; Combined Modality Therapy; Drug Substitution; Endemic Diseases; Humans; | 2020 |
Persistent dermal lesions in a patient with previous history of visceral leishmaniasis.
Topics: Albania; Amphotericin B; Antiprotozoal Agents; Fatal Outcome; Humans; Leishmania infantum; Leishmani | 2021 |
Increased miltefosine tolerance in clinical isolates of Leishmania donovani is associated with reduced drug accumulation, increased infectivity and resistance to oxidative stress.
Topics: Animals; Antiprotozoal Agents; Drug Resistance; Fluorometry; Humans; Leishmania donovani; Leishmania | 2017 |
Recurrence of visceral and muco-cutaneous leishmaniasis in a patient under immunosuppressive therapy.
Topics: Amphotericin B; Antiprotozoal Agents; Biopsy; Female; Humans; Immunocompromised Host; Leishmania; Le | 2017 |
Identification and Functional Validation of a Biomarker for the Diagnosis of Miltefosine Relapse during Visceral Leishmaniasis.
Topics: Antiprotozoal Agents; Biomarkers; Biopsy, Needle; Calpain; Humans; Leishmania donovani; Leishmaniasi | 2018 |
Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Amphotericin B; Antiprotozoal Agents; Bangladesh; Fema | 2018 |
Immunosuppression of Syrian golden hamsters accelerates relapse but not the emergence of resistance in Leishmania infantum following recurrent miltefosine pressure.
Topics: Animals; Antiprotozoal Agents; CD4-Positive T-Lymphocytes; Cricetinae; Cyclophosphamide; Drug Resist | 2019 |
Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance.
Topics: Adolescent; Adult; Antiprotozoal Agents; Child; Child, Preschool; Drug Resistance; Female; Humans; K | 2013 |
Treatment of mucosal leishmaniasis (L. infantum) with miltefosine in a patient with Good syndrome.
Topics: Administration, Oral; Aged; Antiprotozoal Agents; Histocytochemistry; Humans; Immunocompromised Host | 2013 |
One-year follow-up of immunocompetent male patients treated with miltefosine for primary visceral leishmaniasis in Bihar, India.
Topics: Antiprotozoal Agents; Child; Follow-Up Studies; Humans; India; Leishmaniasis, Visceral; Male; Phosph | 2013 |
Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain.
Topics: Antiprotozoal Agents; Humans; Leishmania donovani; Leishmaniasis, Visceral; Phosphorylcholine; Recur | 2013 |
Multiple relapses of visceral leishmaniasis in a patient with HIV in India: a treatment challenge.
Topics: Adult; Amphotericin B; Antiprotozoal Agents; Antiretroviral Therapy, Highly Active; Coinfection; HIV | 2014 |
Failure of miltefosine treatment for visceral leishmaniasis in children and men in South-East Asia.
Topics: Adolescent; Adult; Age Factors; Antiprotozoal Agents; Child; Child, Preschool; Female; Humans; India | 2014 |
Combination Treatment for Visceral Leishmaniasis Patients Coinfected with Human Immunodeficiency Virus in India.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Amphotericin B; Coinfection; D | 2015 |
Lack of correlation between the promastigote back-transformation assay and miltefosine treatment outcome.
Topics: Antiprotozoal Agents; Drug Resistance; Humans; Leishmania donovani; Leishmaniasis, Visceral; Nepal; | 2015 |
PKDL--A Silent Parasite Pool for Transmission of Leishmaniasis in Kala-azar Endemic Areas of Malda District, West Bengal, India.
Topics: Administration, Oral; Adolescent; Adult; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; C | 2015 |
Decline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India.
Topics: Adult; Antiprotozoal Agents; Child; Female; Histocytochemistry; Humans; India; Leishmaniasis, Cutane | 2015 |
Study of efficacy of miltefosine and allopurinol in dogs with leishmaniosis.
Topics: Allopurinol; Animals; Antiprotozoal Agents; Disease Models, Animal; Disease Reservoirs; Dog Diseases | 2009 |
Relapse of visceral leishmaniasis after miltefosine treatment in a Nepalese patient.
Topics: Antiprotozoal Agents; Humans; Leishmaniasis, Visceral; Male; Nepal; Phosphorylcholine; Recurrence; T | 2009 |
Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient.
Topics: AIDS-Related Opportunistic Infections; HIV; HIV Infections; HIV-1; Humans; Itraconazole; Leishmanias | 2010 |
A rare case of Visceral leishmaniasis with multiple relapse and multi-drug unresponsive: successfully treated with combination therapy.
Topics: Adult; Amphotericin B; Antiprotozoal Agents; Drug Resistance, Multiple; Drug Therapy, Combination; H | 2011 |
Leishmania resistance to miltefosine associated with genetic marker.
Topics: Amphotericin B; Antiprotozoal Agents; Drug Resistance; Female; Humans; Inhibitory Concentration 50; | 2012 |
[Leishmaniasis--oral treatment with hexadecylphosphocholine].
Topics: Administration, Oral; Adult; Antiprotozoal Agents; Child; Clinical Trials as Topic; Drug Resistance; | 2004 |
Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe.
Topics: Adult; Amphotericin B; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Europe; Germany; HI | 2006 |
Relapse of new world diffuse cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana after miltefosine treatment.
Topics: Adult; Animals; Antiprotozoal Agents; Humans; Leishmania mexicana; Leishmaniasis, Cutaneous; Male; P | 2006 |
Hexadecyl-phosphorylcholine ointment for treatment of cutaneous leishmaniasis: an animal trial.
Topics: Administration, Cutaneous; Analysis of Variance; Animals; Anti-Infective Agents, Local; Antiprotozoa | 2006 |
Diffuse cutaneous leishmaniasis responds to miltefosine but then relapses.
Topics: Adolescent; Adult; Antiprotozoal Agents; Child; Child, Preschool; Drug Resistance; Female; Humans; L | 2007 |
[Cutaneous leishmaniasis].
Topics: Animals; Biopsy; Cross-Sectional Studies; Diagnosis, Differential; Humans; Leishmania; Leishmaniasis | 2007 |